Compare · BBLG vs ZBH
BBLG vs ZBH
Side-by-side comparison of Bone Biologics Corp (BBLG) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBLG and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $16.88B, about 7523.6x BBLG ($2.2M).
- Over the past year, BBLG is down 72.5% and ZBH is down 5.9% - ZBH leads by 66.6 points.
- ZBH has been more active in the news (15 items in the past 4 weeks vs 1 for BBLG).
- ZBH has more recent analyst coverage (25 ratings vs 0 for BBLG).
- Company
- Bone Biologics Corp
- Zimmer Biomet Holdings Inc.
- Price
- -
- -
- Market cap
- $2.2M
- $16.88B
- 1M return
- -7.46%
- +4.71%
- 1Y return
- -72.52%
- -5.94%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 15
- Recent ratings
- 0
- 25
Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest BBLG
- Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
- SEC Form 10-Q filed by Bone Biologics Corp
- Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Bone Biologics Corp
- SEC Form 10-K filed by Bone Biologics Corp
- SEC Form 4 filed by Chief Financial Officer Walsh Deina H
- SEC Form 4 filed by Chief Executive Officer Frelick Jeff
- Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
- Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Latest ZBH
- SEC Form 4 filed by Officer Noor Jehanzeb
- Group President, Asia Pacific Yi Sang sold $413,216 worth of shares (5,000 units at $82.64), decreasing direct ownership by 16% to 27,251 units (SEC Form 4)
- Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Zimmer Biomet Holdings Inc.
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Bernard Betsy J
- SEC Form 4 filed by Director Hilado Maria Teresa
- SEC Form 4 filed by Director Shapiro Louis
- SEC Form 4 filed by Director Kurdikar Devdatt